001     181839
005     20240229145658.0
024 7 _ |a 10.3390/v14091973
|2 doi
024 7 _ |a pmid:36146781
|2 pmid
024 7 _ |a altmetric:135458873
|2 altmetric
037 _ _ |a DKFZ-2022-02254
041 _ _ |a English
082 _ _ |a 050
100 1 _ |a Materniak-Kornas, Magdalena
|0 0000-0002-2795-597X
|b 0
245 _ _ |a Occurrence of Equine Foamy Virus Infection in Horses from Poland.
260 _ _ |a Basel
|c 2022
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1664202010_27601
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Equine foamy virus (EFVeca) is a foamy virus of non-primate origin and among the least-studied members of this retroviral subfamily. By sequence comparison, EFVeca shows the highest similarity to bovine foamy virus. In contrast to simian, bovine or feline foamy viruses, knowledge about the epidemiology of EFVeca is still limited. Since preliminary studies suggested EFVeca infections among horses in Poland, we aimed to expand the diagnostics of EFVeca infections by developing specific diagnostic tools and apply them to investigate its prevalence. An ELISA test based on recombinant EFVeca Gag protein was developed for serological investigation, while semi-nested PCR for the detection of EFVeca DNA was established. 248 DNA and serum samples from purebred horses, livestock and saddle horses, Hucul horses and semi-feral Polish primitive horses were analyzed in this study. ELISA was standardized, and cut off value, sensitivity and specificity of the test were calculated using Receiver Operating Characteristic and Bayesian estimation. Based on the calculated cut off, 135 horses were seropositive to EFVeca Gag protein, while EFVeca proviral DNA was detected in 85 animals. The rate of infected individuals varied among the horse groups studied; this is the first report confirming the existence of EFVeca infections in horses from Poland using virus-specific tools.
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a ELISA
|2 Other
650 _ 7 |a PCR
|2 Other
650 _ 7 |a diagnostics
|2 Other
650 _ 7 |a equine foamy virus
|2 Other
650 _ 7 |a horses
|2 Other
650 _ 7 |a prevalence
|2 Other
700 1 _ |a Rożek, Wojciech
|b 1
700 1 _ |a Rola, Jerzy
|0 0000-0002-0615-4444
|b 2
700 1 _ |a Osiński, Zbigniew
|b 3
700 1 _ |a Löchelt, Martin
|0 P:(DE-He78)9c8a7dc019ff6a8d3da29f2069054a6f
|b 4
|u dkfz
700 1 _ |a Kuźmak, Jacek
|b 5
773 _ _ |a 10.3390/v14091973
|g Vol. 14, no. 9, p. 1973 -
|0 PERI:(DE-600)2516098-9
|n 9
|p 1973
|t Viruses
|v 14
|y 2022
|x 1999-4915
909 C O |o oai:inrepo02.dkfz.de:181839
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)9c8a7dc019ff6a8d3da29f2069054a6f
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-05-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-05-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-05-04
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b VIRUSES-BASEL : 2021
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-08-26T14:29:58Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-08-26T14:29:58Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-08-26T14:29:58Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-15
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-15
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b VIRUSES-BASEL : 2021
|d 2022-11-15
920 1 _ |0 I:(DE-He78)F030-20160331
|k F030
|l F030 Virale Transformationsmechanismen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F030-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21